Australia - English - Department of Health (Therapeutic Goods Administration)

bio-rad laboratories pty ltd - ct833 - clinical chemistry substrate ivds - ivds quality control that are intented to be used to monitor the precision of laboratory testing of clinical chemistry substrate .

Australia - English - Department of Health (Therapeutic Goods Administration)

bio-rad laboratories pty ltd - ct1237 - clinical chemistry trace element ivds - intended to be used as a quality control material to monitor the precision of laboratory testing procedures for clinical chemistry trace elements in a clinical specimen.

Australia - English - Department of Health (Therapeutic Goods Administration)

bio-rad laboratories pty ltd - ct845 - clinical chemistry tumour marker ivds - quilaty control ivds that are intended to be used to monitor the precision of laboratory testing procedures for determination of clinical chemistry tumour markers.

Australia - English - Department of Health (Therapeutic Goods Administration)

bio-rad laboratories pty ltd - ct847 - clinical chemistry vitamin and mineral ivds - quialty control ivds that are intended to be used for monitoring the precision of laboratory testing procedures for clinical chemistry vitamins and minerals .

Australia - English - Department of Health (Therapeutic Goods Administration)

bio-rad laboratories pty ltd - ct974 - clinical chemistry-specific protein ivds - quilaty control that are intended to be used to monitor the precision of laboratory testing procedures for the analytes of clinical chemistry specific protein ivds

Australia - English - Department of Health (Therapeutic Goods Administration)

bio-rad laboratories pty ltd - ct889 - multiple clinical chemistry constituent ivds - quilaty control ivds that are intended to be used to monitor the precision of laboratory testing procedures for multiple clinical chemistry constituent

United States - English - NLM (National Library of Medicine)

caraco pharmaceutical laboratories, ltd. - indomethacin (unii: xxe1cet956) (indomethacin - unii:xxe1cet956) - indomethacin 25 mg - carefully consider the potential benefits and risks of indomethacin capsules and other treatment options before deciding to use indomethacin. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings ). indomethacin has been found effective in active stages of the following: - moderate to severe rheumatoid arthritis including acute flares of chronic disease. - moderate to severe ankylosing spondylitis. - moderate to severe osteoarthritis. - acute painful shoulder (bursitis and/or tendinitis). - acute gouty arthritis. indomethacin is contraindicated in patients with known hypersensitivity to indomethacin or the excipients (see description ). indomethacin should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other nsaids. severe, rarely fatal, anaphylactic/anaphylactoid reactions to nsaids have been reported in such patients (see warnings: anaphylactic/anaphylactoid reactions , and

United States - English - NLM (National Library of Medicine)

caraco pharmaceutical laboratories, ltd. - oxaprozin (unii: mhj80w9lrb) (oxaprozin - unii:mhj80w9lrb) - oxaprozin 600 mg - carefully consider the potential benefits and risks of oxaprozin tablet, usp and other treatment options before deciding to use oxaprozin tablet, usp. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings). oxaprozin tablet, usp is indicated: - for relief of the signs and symptoms of osteoarthritis - for relief of the signs and symptoms of rheumatoid arthritis - for relief of the signs and symptoms of juvenile rheumatoid arthritis oxaprozin tablet, usp is contraindicated in patients with known hyper-sensitivity to oxaprozin. oxaprozin tablet, usp should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other nsaids. severe, rarely fatal, anaphylactic-like reactions to nsaids have been reported in such patients (see warnings, anaphylactoid reactions and precautions, preexisting asthma). oxaprozin tablet, usp is contraindicated for the treatment of peri-operative pain in the setti

United States - English - NLM (National Library of Medicine)

caraco pharmaceutical laboratories, ltd. - flurbiprofen (unii: 5gro578klp) (flurbiprofen - unii:5gro578klp) - tablet - 50 mg - carefully consider the potential benefits and risks of flurbiprofen tablet, usp and other treatment options before deciding to use flurbiprofen tablet, usp. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings). flurbiprofen tablet, usp is indicated: - for relief of the signs and symptoms of rheumatoid arthritis. - for relief of the signs and symptoms of osteoarthritis. flurbiprofen tablets, usp are contraindicated in patients with known hypersensitivity to flurbiprofen. flurbiprofen tablet, usp should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other nonsteroidal anti-inflammatory drugs. severe, rarely fatal, anaphylactic-like reactions to nonsteroidal anti-inflammatory drugs have been reported in such patients (see warnings, anaphylactoid reactions, and precautions, preexisting asthma). flurbiprofen tablet, usp is contraindicated for the treatment of peri-operative pain

United States - English - NLM (National Library of Medicine)

caraco pharmaceutical laboratories, ltd. - meloxicam (unii: vg2qf83cgl) (meloxicam - unii:vg2qf83cgl) - tablet - 7.5 mg - carefully consider the potential benefits and risks of meloxicam tablets and other treatment options before deciding to use meloxicam tablets. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings). meloxicam tablets are indicated for relief of the signs and symptoms of osteoarthritis and rheumatoid arthritis. meloxicam tablet is contraindicated in patients with known hypersensitivity to meloxicam. meloxicam tablets should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other nsaids. severe, rarely fatal, anaphylactic-like reactions to nsaids have been reported in such patients (see warnings, anaphylactoid reactions, and precautions, pre-existing asthma). meloxicam tablet is contraindicated for the treatment of peri-operative pain in the setting of coronary artery bypass graft (cabg) surgery (see warnings).